Carreira, PIsenberg, D2021-11-222021-11-222019Rheumatology (Oxford). 2019 Mar 1;58(3):382-387.http://hdl.handle.net/10400.17/3913SLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.engHCC DAUTOIMAntibodies, Monoclonal, Humanized / therapeutic useBiological Products / therapeutic use*HumansImmunoglobulin Fab Fragments / therapeutic useImmunologic Factors / therapeutic use*Interferon-alpha / therapeutic useLupus Erythematosus, Systemic / drug therapy*Polyethylene Glycols / therapeutic useRituximab / therapeutic useTreatment Outcomejournal article10.1093/rheumatology/key064.